CCR Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The NCI Center for Cancer Research (CCR) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 17 clinical trials at NIH that match your search criteria

Cancer by type/disease: Melanoma

Trial and Protocol Number Melanoma	Principal Investigator	Referral Contact
Phase II
Phase II Study of Metastatic Melanoma Using a Chemoradiation Lymphodepleting Conditioning Regimen Followed by Infusion of Anti-Mart-1 and Anti-gp100 TCR-Gene Engineered Lymphocytes and Peptide Vaccines NCI-09-C-0051	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Transfer of Autologous T Cells Transduced With the Anti-MART-1 F5 T Cell Receptor in High Risk Melanoma NCI-08-C-0162	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Tumor Reactive Peripheral Blood Lymphocytes (PBL) and High or Low Dose Aldesleukin NCI-08-C-0104	Udai Kammula 301-435-8606	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes and ALVAC Virus Immunization NCI-08-C-0056	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-gp100:154-162 TCR-Gene Engineered Lymphocytes and ALVAC Virus Immunization NCI-08-C-0055	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase II Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma NCI-07-C-0176	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes NCI-07-C-0175	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-gp100: 154:162 TCR Gene Engineered Lymphocytes NCI-07-C-0174	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High Risk Melanoma NCI-06-C-0069	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Treatment of Patients With Metastatic Melanoma Using Cloned Lymphocytes Following Administration of a Non-Myeloablative but Lymphocyte Depleting Regimen NCI-99-C-0158	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	June A. Kryk 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase I/II
Phase I/II Study Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Allogeneic Tumor-Reactive Lymphocyte Cell Line DMF5 in Metastatic Melanoma NCI-07-C-0210	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase I
A Phase I Study of Subcutaneous "CYT 107" (Interleukin-7) in Refractory Metastatic Melanoma or Renal Cell Carcinoma NCI-07-C-0114	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
A Phase I Study of the Safety and Efficacy of GC1008: A Human Anti-Transforming Growth Factor-beta (TGF-β) Monoclonal Antibody in Patients With Advanced Renal Cell Carcinoma or Malignant Melanoma NCI-06-C-0200	John C. Morris 301-402-2912	Brenda Roberson 301-435-4733 broberson@mail.nih.gov
No Phase
Dermoscopic Diagnosis, Histopathological Correlation, and Cellular Immortalization of Melanocytic Nevi and Primary Cutaneous Melanoma NCI-06-C-0060	Thomas Hornyak 301-451-1926	Susan Booher 301-402-1474 boohers@mail.nih.gov

Trial and Protocol Number Solid Tumor	Principal Investigator	Referral Contact
Phase II
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes NCI-08-C-0121	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase I
A Phase I, Open-Label Study of MEDI-547 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biologic Activity of Intravenous Administration in Subjects With Refractory Solid Tumors Associated With EphA2 Expression NCI-09-C-0168	Elise C. Kohn 301-402-2726	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors NCI-09-C-0019	Elise C. Kohn 301-402-2726	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov

For additional studies that may be appropriate for your disease type, please search under Solid Tumor.